At last, there has been some reported progress on the PCV2 (porcine
circovirus) / PMWS (post-weaning multisystemic wasting syndrome) vaccine front
At the recent International Symposium of Emerging and Re-emerging Pig
Diseases, held in the delightful and historic city of Krakow in Poland the
latest information on porcine circovirus vaccine development in Europe was
Quim Segales from University of Barcelona, Spain, demonstrated the protective
effect of Intervet's piglet vaccine, Porcilis PCVÂ® in an artificial infection
study. The vaccine was given twice to colostrum-fed piglets and gave a high
level of protection against a virus challenge from EU and US PCV2 isolates.
European fields trials
Successful European field trials, which mirrored earlier findings in N.
America, were carried out with Boehringer Ingelheim's Ingelvac CircoFLEXÂ®, a
single dose piglet vaccine.
British consultant practitioner, Nigel Woolfenden, described a blinded, fully
controlled study where piglets were vaccinated or injected with a placebo at 3
weeks of age and moved to the nursery at 4 weeks after weaning. Mortality from
, in the enzootic pneumonia and PRRS
-free farm was reduced from 14.3% to 4.6%
(-9.7%) between weaning and slaughter and the surviving pigs weighed 6.8kg
heavier than the placebo controls.
The onset of the PCV2 viraemia and the start of the detrimental effects
occurred at approximately 8 weeks of age. In a similar German study, Mathias
Ritzmann from Ludwig Maximilian's University, Munich reported on a trial in a
multi-sourced growing/finishing herd with mixed PMWS and porcine respiratory
disease complex (PRDC) problems. The viraemia started at 11 weeks of age and
peaked 2-3 weeks later. The viraemia coincided with a divergence in growth rate
between the vaccinated and control pigs. At the end of the study, the mortality
was reduced from 9.4 to 5% (-4.4%) and the pig's bodyweight was 4.6kg
Merial celebrated, during the conference, the announcement that their PCV2
vaccine for sows, CircovacÂ®, has now received EC approval and should be
available across the EU fairly soon. This is the first EU approval for a PCV2
vaccine. The vaccine should stabilize sow herd immunity and give protection of
the piglet for up to 5 weeks after the transfer of passive antibodies to the
piglets through colostrum uptake. Thereby, lesions in lymphoid tissues and
mortality associated with PCV2 infection should be reduced.
At long last, with this exciting new PCV2 vaccine information coming through
in Europe, we are catching up on the N. Americans and soon we will have the
tools to control this depressing circovirus wasting